Post-Ipi Systemic Tx | # pts | # pts achieving ≥1yr disease control* |
---|---|---|
Cytotoxic Therapy | 11/80 (14%) | 5/10 (50%) |
Anti-PD-1/PD-L1 | 16/80 (20%) | 11/15 (73%) |
BRAF inhibitor | 10/80 (13%) | 7/9 (78%) |
Ipi re-induction | 18/80 (23%) | 5/16 (31%) |
Other clinical trial | 13/80 (16%) | 1/13 (8%) |